Halothane for status asthmaticus in the intensive care unit--a case report.
A case report is presented demonstrating the beneficial beta2 stimulating effect of halothane in a patient with status asthmaticus unresponsive to adequate conventional therapy. Twenty-four hours after the commencement of therapy, 0.5 per cent of 1.0 per cent halothane was administered for one hour with sustained reductions in peak inspiratory airway pressure and increases in dynamic and static effective compliances.
D000328:Adult; D001241:Aspirin / Q000009:adverse effects; D001249:Asthma / Q000139:chemically induced / Q000188:drug therapy*; D006221:Halothane / Q000627:therapeutic use*; D006801:Humans; D007362:Intensive Care Units; D008297:Male
D001241:Aspirin; D006221:Halothane